These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. The Differential Diagnosis and Treatment of Atypical Parkinsonism. Levin J; Kurz A; Arzberger T; Giese A; Höglinger GU Dtsch Arztebl Int; 2016 Feb; 113(5):61-9. PubMed ID: 26900156 [TBL] [Abstract][Full Text] [Related]
10. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882 [TBL] [Abstract][Full Text] [Related]
11. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028 [TBL] [Abstract][Full Text] [Related]
12. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675 [TBL] [Abstract][Full Text] [Related]
13. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900 [TBL] [Abstract][Full Text] [Related]
14. Serum Oligomeric α-Synuclein and p-tau181 in Progressive Supranuclear Palsy and Parkinson's Disease. Cristiani CM; Scaramuzzino L; Quattrone A; Parrotta EI; Cuda G; Quattrone A Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999992 [TBL] [Abstract][Full Text] [Related]
15. Plasma α-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease. Ren J; Pan C; Wang Y; Xue C; Lin H; Xu J; Wang H; Zhang W; Xu P; Chen Y; Liu W J Neurochem; 2022 Jun; 161(6):506-515. PubMed ID: 35234288 [TBL] [Abstract][Full Text] [Related]
16. The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias. Stamelou M; Diehl-Schmid J; Hapfelmeier A; Kontaxopoulou D; Stefanis L; Oertel WH; Bhatia KP; Papageorgiou SG; Höglinger GU Parkinsonism Relat Disord; 2015 Oct; 21(10):1264-8. PubMed ID: 26324212 [TBL] [Abstract][Full Text] [Related]
17. Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model. Lin CH; Chiu SI; Chen TF; Jang JR; Chiu MJ Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32967146 [TBL] [Abstract][Full Text] [Related]
19. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721 [TBL] [Abstract][Full Text] [Related]
20. Comparison of dystonia between Parkinson's disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism. Yoon WT Neurol Neurochir Pol; 2018; 52(1):48-53. PubMed ID: 29196058 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]